Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Astellas Signs Agreement With NeurogesX For Qutenza

This article was originally published in PharmAsia News

Executive Summary

Astellas June 23 signed a licensing agreement with U.S. biotech NeurogesX and obtained exclusive rights to distribute, develop and market Qutenza in Europe, the Middle East and Africa. Astellas subsidiary Astellas Europe will pay 30 million euros in a one-time payment and will pay 5 million euros for the option to co-develop and co-market NGX-1998. Qutenza is an agent to relieve pain associated with peripheral neuropathic pain conditions. It obtained an approval from the European Medicines Agency for non-diabetic pain relief this May. (Click here for more - Japanese language
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC072032

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel